In Neurofibromatosis type 2, bilateral vestibular schwannomas can affect the auditory nerves and, in select cases, pose risks of brainstem compression, hearing impairment, and facial nerve dysfunction — a clinical situation where the threshold for active management requires careful assessment.
NF2's main clinical features include bilateral vestibular schwannomas affecting auditory nerves, causing hearing loss and imbalance. Not all tumors require treatment; intervention is indicated when brainstem complications, hearing impairment, and/or facial nerve dysfunction are at risk.
Management in this setting may include surgical intervention or, where appropriate, a systemic medical option from a specific antibody class recognised as first-line therapy. The full regimen — covering selection criteria, sequencing, and conditions for each modality — is detailed in the structured protocol.
Goals: Tumor reduction and auditory improvement.
NF2's main clinical features include bilateral vestibular schwannomas, affecting auditory nerves, causing hearing loss and imbalance.
Not all tumors require treatment, indicated when brainstem complications, hearing impairment, and/or facial nerve dysfunction are at risk.
Surgery typically manages vestibular schwannomas, especially in NF2 patients.
Radiotherapy may be considered, though its role in NF2 vestibular schwannoma management is less clear.
Bevacizumab, a monoclonal antibody, is used as first-line medical therapy for NF2-associated vestibular schwannomas.
Studies show bevacizumab might induce tumor reduction and auditory improvement in some NF2 patients.
View source ↗